（以下无正文） 王庆太、曹晓兵关于要约收购提示性公告期满 90 日的说明 王庆太和曹晓兵（以下简称"收购人"）及其一致行动人崔子浩拟 通过协议转让方式取得西藏多瑞医药股份有限公司（以下简称"多瑞 医药"或"上市公司"）控制权。2025 年 10 月 14 日，上市公司披露了 收购人及其一致行动人崔子浩签署的《西藏多瑞医药股份有限公司要 约收购报告书摘要》，以协议转让为前提，收购人拟通过部分要约收 购方式进一步增持上市公司股份，并就要约收购事项作出提示性公告。 截至本说明出具日，距本次要约收购提示性公告已满 90 日，根 据《上市公司收购管理办法》等法律法规要求，收购人就本次要约收 购的工作进展情况说明如下： 2025 年 10 月 14 日，收购人已将 124,688,160 元（超过本次要约 收购所需最高资金总额的 20%）作为履约保证金存入证券登记结算机 构指定的账户，作为本次要约收购的履约保证。 截至本说明出具日，协议转让股份过户登记已完成，收购人将尽 快披露要约收购报告书。本次收购要约尚未生效，具有不确定性，提 醒广大投资者充分关注上述风险及后续公告。 特此说明。 （本页无正文，为《王庆太、曹晓兵关于 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2026-001 西藏多瑞医药股份有限公司 关于注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 心建设项目"，将募投项目"学术推广及营销网络扩建项目"结项，并 将剩余资金用于偿还银行贷款和永久补充流动资金。具体内容详见公 司于 2025 年 10 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露的 相关公告。 鉴于公司的募集资金已按上述要求使用完毕，为降低公司管理成 本、规范银行账户使用，公司对上述募集资金专户办理了注销手续。 截至本公告披露日，公司已办理完成上述募集资金专户的注销手 续，并及时通知了保荐机构和保荐代表人。上述募集资金专户注销后， 相应的募集资金监管协议随之终止。 二、募集资金存放和管理情况 为了规范募集资金的管理和使用，保护投资者的利益，根据《上 市公司募集资金监管规则》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所创业板上市公司规范运作指引》等法律、法规和规 范性文件要求，以及公司《募集资金管理制度》的规定， ...

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical has shown significant trading activity, with a notable increase in financing buy-ins and a high financing balance relative to its market value [1] - On December 24, Duorui Pharmaceutical's stock rose by 2.09%, with a trading volume of 59.29 million yuan and a net financing buy of 4.89 million yuan [1] - The company's financing balance reached 214 million yuan, accounting for 5.09% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period, while the average circulating shares per person increased by 19.90% to 12,576 shares [2] - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%, and a net profit attributable to shareholders of -79.73 million yuan, representing a significant decline of 366.82% [2] - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2]

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical's stock performance and financial metrics indicate a challenging period, with significant declines in revenue and net profit, alongside high financing levels [1][2]. Group 2 - On December 23, Duorui Pharmaceutical's stock rose by 3.14%, with a trading volume of 72.61 million yuan. The financing buy-in amount was 3.21 million yuan, while the financing repayment was 7.48 million yuan, resulting in a net financing buy of -4.28 million yuan [1]. - As of December 23, the total financing and securities lending balance for Duorui Pharmaceutical was 209 million yuan, accounting for 5.08% of its market capitalization, which is above the 90th percentile level over the past year [1]. - The company has not engaged in securities lending activities on December 23, with no shares sold or repaid, indicating a high level of inactivity in this area [1]. - Duorui Pharmaceutical, established on December 22, 2016, and listed on September 29, 2021, focuses on the research, production, and sales of chemical drug formulations and their raw materials. The revenue composition is as follows: formulations 37.60%, intermediates 35.78%, raw materials 21.64%, and others 4.98% [1]. - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period, while the average circulating shares per person increased by 19.90% to 12,576 shares [2]. - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%, and a net profit attributable to shareholders of -79.73 million yuan, representing a year-on-year decline of 366.82% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].

来源：金综科技 根据公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方式出售已回购股 份，实施期限为自本公告披露之日起15个交易日后的6个月内(即2026年1月14日至2026年7月13日，根据 中国证监会及深圳证券交易所相关规定禁止出售的期间除外)，本次拟出售回购股份不超过104.45万 股，占公司总股本的1.31%，出售价格根据二级市场价格确定。 特别声明：以上内容仅代表作者本人的观点或立场，不代表新浪财经头条的观点或立场。如因作品内 容、版权或其他问题需要与新浪财经头条联系的，请于上述内容发布后的30天内进行。 12月20日，多瑞医药(301075.SZ)发布公告，公司董事会审议通过了《关于回购股份集中竞价减持计划 的议案》。 ...

Core Viewpoint - Duori Pharmaceutical (301075.SZ) announced the plan to sell repurchased shares through a centralized bidding method, with a total of up to 1,044,500 shares, representing 1.31% of the company's total share capital [1] Group 1 - The sale period for the repurchased shares will be from January 14, 2026, to July 13, 2026, excluding the periods prohibited by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [1] - The selling price of the repurchased shares will be determined based on the secondary market price [1]

Group 1 - The core viewpoint of the article is that Duorui Pharmaceutical (301075.SZ) has decided to terminate several fundraising projects and return the remaining funds to repay bank loans and supplement working capital permanently [1] - The company has approved the termination of the following projects: "Annual production of 16 million bags of sodium acetate injection (Phase III project)", "New product development project", and "Tibet headquarters and R&D center construction project" [1] - The project "Academic promotion and marketing network expansion project" has been concluded [1] Group 2 - To implement the termination of the aforementioned fundraising projects, Hubei Duorui plans to reduce its registered capital by 241.9 million yuan [1] - After the capital reduction, Hubei Duorui's registered capital will change from 271.9 million yuan to 30 million yuan [1]

多瑞医药(301075.SZ)公告，公司董事会审议通过了《关于回购股份集中竞价减持计划的议案》，根据 公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方式出售已回购股份,实 施期限为自本公告披露之日起15个交易日后的6个月内(即2026年1月14日至2026年7月13日，根据中国证 监会及深圳证券交易所相关规定禁止出售的期间除外)，本次拟出售回购股份不超过104.45万股，占公 司总股本的1.31%，出售价格根据二级市场价格确定。 ...

Core Viewpoint - The company, Duori Pharmaceutical (301075.SZ), has approved a share repurchase plan to sell back shares through centralized bidding, with a total of up to 1.0445 million shares, representing 1.31% of the company's total share capital [1] Group 1 - The board of directors has passed a resolution regarding the share repurchase plan [1] - The repurchased shares will be sold within a period starting 15 trading days after the announcement and lasting for 6 months, specifically from January 14, 2026, to July 13, 2026 [1] - The selling price of the repurchased shares will be determined based on the secondary market price [1]

每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 王晓波） 每经AI快讯，多瑞医药（SZ 301075，收盘价：50.9元）12月19日晚间发布公告称，西藏多瑞医药股份 有限公司于2025年12月19日召开第二届董事会第二十五次会议，审议通过了《关于回购股份集中竞价减 持计划的议案》，根据公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方 式出售已回购股份实施期限为自本公告披露之日起15个交易日后的6个月内（即2026年1月14日至2026年 7月13日，本次拟出售回购股份不超过约104万股，占公司总股本的1.31%，出售价格根据二级市场价格 确定。 截至发稿，多瑞医药市值为41亿元。 2024年1至12月份，多瑞医药的营业收入构成为：医药制造业占比57.85%，其他占比42.15%。 ...